Challenge
MIGAL scientists wanted to fast-track development of a vaccine for COVID-19 based on their existing virus research.
We realized we needed a flexible system in order to respond to the rapid changes of the viruses, specifically for the SARS-CoV-2.
Solution
The institute uses BIOVIA to scale up their research and study mutations of the SARS-CoV-2 virus.
Benefits
With BIOVIA, MIGAL scientists can streamline their research and accelerate actionable scientific insights.